Alnylam Pharmaceuticals, Inc.
ALNY
$298.58
-$3.88-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 594.19M | 593.17M | 500.92M | 659.83M | 494.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 594.19M | 593.17M | 500.92M | 659.83M | 494.33M |
| Cost of Revenue | 71.04M | 102.82M | 85.91M | 68.67M | 65.98M |
| Gross Profit | 523.15M | 490.35M | 415.01M | 591.15M | 428.36M |
| SG&A Expenses | 239.95M | 295.34M | 220.99M | 248.40M | 210.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 576.11M | 698.33M | 577.82M | 611.21M | 537.77M |
| Operating Income | 18.08M | -105.16M | -76.91M | 48.61M | -43.44M |
| Income Before Tax | -41.60M | -193.96M | -108.66M | -11.17M | -63.59M |
| Income Tax Expenses | 15.88M | -110.20M | 2.91M | 5.72M | 2.35M |
| Earnings from Continuing Operations | -57.48M | -83.76M | -111.57M | -16.89M | -65.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.48M | -83.76M | -111.57M | -16.89M | -65.94M |
| EBIT | 18.08M | -105.16M | -76.91M | 48.61M | -43.44M |
| EBITDA | 32.48M | -90.99M | -62.92M | 63.62M | -29.92M |
| EPS Basic | -0.44 | -0.65 | -0.87 | -0.13 | -0.52 |
| Normalized Basic EPS | -0.20 | -0.94 | -0.52 | -0.05 | -0.32 |
| EPS Diluted | -0.44 | -0.65 | -0.87 | -0.13 | -0.52 |
| Normalized Diluted EPS | -0.20 | -0.94 | -0.52 | -0.05 | -0.32 |
| Average Basic Shares Outstanding | 129.68M | 129.12M | 128.59M | 126.73M | 126.14M |
| Average Diluted Shares Outstanding | 129.68M | 129.12M | 128.59M | 126.73M | 126.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |